Novavax announced initiation of PREVENT-19 COVID-19 vaccine phase 3 trial booster study
On Dec. 21, 2021, Novavax announced that the first booster doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based…
-
-
World Health Organization granted scond Emergency Use listing for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the World Health Organization (WHO) had granted a second Emergency Use…
-
European Commission granted conditional Marketing Authorization for Novavax COVID-19 vaccine
On Dec. 20, 2021, Novavax announced that the European Commission (EC) had granted Novavax conditional marketing authorization (CMA)…
-
Moderna announced preliminary booster data and updated strategy to address Omicron variant
On Dec. 20, 2021, Moderna announced preliminary neutralizing antibody data against the Omicron variant following the Company’s booster…
-
Novavax and Serum Institute of India announced WHO Emergency Use listing for NVX-CoV2373 COVID-19 vaccine
On Dec. 17, 2021, Novavax and SK bioscience announced that the World Health Organization (WHO) had granted Emergency…
-
Novavax announced submission of New Drug Application in Japan for approval of COVID-19 vaccine
On Dec. 15, 2021, Novavax announced the submission of a New Drug Application to the Ministry of Health,…
-
Pfizer announced additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate
On Dec. 14, 2021, Pfizer announced final results from an analysis of all 2,246 adults enrolled in its…
-
Moderna and Australia announced collaboration to bring mRNA manufacturing to Australia
On Dec. 13, 2021, Moderna announced an agreement with the Australian Government to build a state-of-the-art messenger RNA…
-
Novavax filed for Emergency Use of COVID-19 vaccine in the United Arab Emirates
On Dec. 13, 2021, Novavax announced that it had submitted a regulatory filing to the Ministry of Health…
-
Moderna announced additional 20 million doses of COVID-19 vaccine to COVAX for supply in 2021 and additional supply for 2022
On Dec. 10, 2021, Moderna announced an amendment to its existing contract with Gavi, the Vaccine Alliance, to…
-
CytoDyn submited protocol with FDA for phase 3 Registrational trial of leronlimab for critically ill COVID-19 population
On Dec. 9, 2021, CytoDyn announced that it had submitted a Phase 3, randomized, double blind, placebo controlled…
-
Moderna launched AI Academy in partnership with Carnegie Mellon University
On Dec. 9, 2021, Moderna announced the launch of its Artificial Intelligence Academy, an innovative initiative that will…
-
Pfizer and BioNTech provided update on Omicron variant
On Dec. 8, 2021, Pfizer and BioNTech announced results from an initial laboratory study demonstrating that serum antibodies…
-
Llama antibodies could help fight SARS-CoV-2 variants
On Dec. 7, 2021, Rockefeller University scientists announced a study had demonstrated the therapeutic potential of an unusual…
-
Sorrento announced publication of novel SARS-CoV-2 main protease inhibitors for potential treatment of COVID-19 patients infected with SARS-CoV-2
On Dec. 5, 2021, Sorrento Therapeutics announced the peer-reviewed publication of a series of novel SARS-CoV-2 MPro inhibitors…
-
Roche announced the launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark
On Dec. 5, 2021, Roche announced that its planned to launch the SARS-CoV-2 & Flu A/B Rapid Antigen…
-
HHS study showed 63-fold increase in Medicare Telehealthutilization during the Pandemic
On Dec. 3, 2021, a report from the U.S. Department of Health and Human Services (HHS) found that…
-
T2 Biosystems T2SARS-CoV-2 panel detected Omicron variant
On Dec. 1, 2021, T2 Biosystems announced that its T2SARS-CoV-2 Panel detected the Omicron COVID-19 variant (B.1.1.529). The…
-
Moderna announced supply agreement with the UK for additional 60 million doses of COVID-19 vaccine in 2022 and 2023
On Dec. 1, 2021, Moderna announced a revised supply agreement with the UK government for up to 60…
-
SIGA announced Health Canada regulatory approval of Oral TPOXX
On Dec. 1, 2021, SIGA Technologies announced that Health Canada had approved oral TPOXX (tecovirimat) as an extraordinary…
-
INOVIO Announced Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants
On Nov. 30, 2021, Inovio Pharma announced the company was rapidly moving to evaluate its COVID-19 DNA vaccine…
-
Hologic’s COVID-19 tests detected Omicron variant
On Nov. 29, 2021, Hologic announced that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of…
-
Biotechnology | Cartoons - Original | CDC | COVID-19 | Diagnostics | FDA | Infectious Disease | Medicine | NIH | Non-Profit Research | Pharmaceutical | Therapeutics | U.S. Congress | Vaccine
COVID-19 roller coaster
The COVID-19 Roller Coaster is a wild ride! Strap yourself in and hold on for the ride of…
-
Merck and Ridgeback Biotherapeutics provided update on results from MOVe-OUT study of Molnupiravir in adults with COVID-19
On Nov. 26, 2021, Merck provided an update on the MOVe-OUT study of molnupiravir, an investigational oral antiviral…
-
Pfizer and BioNTech received positive CHMP opinion for COMIRNATY in children 5 to under 12 years of age in the EU
On Nov. 25, 2021, Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP)…
-
Novavax filed for interim authorization of COVID-19 vaccine in singapore
On Nov. 24, 2021, Novavax announced its submission to the Singapore Health Sciences Authority for interim authorization of…
-
Johnson & Johnson COVID-19 vaccine fully approved by Health Canada to prevent COVID-19 in ages 18 years and older
On Nov. 24, 2021, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) had issued Emergency…
-
FDA authorized InBios COVID-19 over-the-counter antigen test
On Nov. 22, 2021, the U.S. Food and Drug Administration (FDA) authorized another over-the-counter (OTC) COVID-19 antigen test. The…
-
Tonix Pharmaceuticals announced publication of paper on antiviral SARS-CoV-2 inhibitor, TNX-3500, in JCI Insight
On Nov. 22, 2021, Tonix Pharmaceuticals announced the publication of ‘Sangivamycin is highly effective against SARS-CoV-2 in vitro…
-
FDA announced FDA authorization of Moderna’s booster dose of COVID-19 vaccine in the U.S. for adults 18 years and older
On Nov. 19, 2021, the U.S. Food and Drug Administration (FDA) announced that it had extended the emergency…
